For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study for Patients With Soft Tissue Sarcoma
This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
In order to participate you must meet the following criteria:
- Have pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma.
- Have a planned definitive surgical resection of the primary tumor.
- Have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration.
This is a partial list of inclusion and exclusion criteria.